Richard F Ambinder

Summary

Publications

  1. ncbi request reprint Epstein-Barr virus-associated lymphoproliferative disorders
    Richard F Ambinder
    Hematologic Malignancies Division, Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building, Rm 389, 1650 Orleans St, Baltimore, MD 21231, USA
    Rev Clin Exp Hematol 7:362-74. 2003
  2. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
  3. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
  4. pmc Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, MD, USA
    Leuk Lymphoma 54:483-90. 2013
  5. pmc Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors
    De Xue Fu
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Nat Med 14:1118-22. 2008
  6. pmc Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    Jennifer A Kanakry
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:602-6. 2013
  7. pmc Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:365-73. 2011
  8. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
  9. pmc Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
    Jennifer A Kanakry
    Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA
    Blood 121:3547-53. 2013
  10. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010

Detail Information

Publications65

  1. ncbi request reprint Epstein-Barr virus-associated lymphoproliferative disorders
    Richard F Ambinder
    Hematologic Malignancies Division, Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building, Rm 389, 1650 Orleans St, Baltimore, MD 21231, USA
    Rev Clin Exp Hematol 7:362-74. 2003
    ..Knowledge of the EBV association is not only important for understanding the pathogenesis of these tumors, but is increasingly important for diagnosis, monitoring and treatment...
  2. pmc High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 115:3224-30. 2010
    ..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)...
  3. pmc Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome
    Yvette L Kasamon
    Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 16:482-9. 2010
    ..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide...
  4. pmc Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, MD, USA
    Leuk Lymphoma 54:483-90. 2013
    ..Seventeen (81%) received intensification (median 30 days to intensification). Brief, anthracycline-sparing, intensive cyclophosphamide (BASIC) therapy yields durable remissions in poorer-risk BL/atypical BL...
  5. pmc Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors
    De Xue Fu
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Nat Med 14:1118-22. 2008
    ..Bortezomib-induced enzyme-targeted radiation therapy illustrates the possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy...
  6. pmc Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma
    Jennifer A Kanakry
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 19:602-6. 2013
    ..AlloBMT may be appropriate in first remission in select high-risk cases...
  7. pmc Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:365-73. 2011
    ..Thus, 4-HC-purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas...
  8. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  9. pmc Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
    Jennifer A Kanakry
    Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA
    Blood 121:3547-53. 2013
    ..These results confirm that plasma EBV-DNA is highly concordant with EBER-ISH in HL and suggest that it may have prognostic utility both at baseline and after therapy. This trial was registered at www.clinicaltrials.gov as #NCT00003389...
  10. pmc High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up
    Robert A Brodsky
    Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
    Blood 115:2136-41. 2010
    ....
  11. pmc Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning
    Yvette L Kasamon
    Johns Hopkins University, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 15:242-8. 2009
    ..The favorable outcome achieved here in historically poor-risk patients warrants further, more definitive investigation of treatment modification based on early PET scanning...
  12. pmc Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors
    Jennifer A Kanakry
    Department of Oncology, Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, Maryland
    Biol Blood Marrow Transplant 21:2115-22. 2015
    ..This study was registered at www.clinicaltrials.gov as NCT00946023...
  13. pmc A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 38:2892-903. 2011
    ..The authors present here an adaptation of the simple sphere-based model from which cellular level dosimetry for macroscopic tumors and their end point quantities, such as TCP, may be extrapolated more reliably...
  14. pmc Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood
    Lan Lin
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:2496-502. 2009
    ....
  15. pmc Imaging virus-associated cancer
    De Xue Fu
    Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Curr Pharm Des 14:3048-65. 2008
    ..Under certain conditions, and particularly during pharmacologic stimulation, gammaherpesviruses will express genes that enable imaging and therapy in vivo. The techniques discussed are readily translatable to the clinic...
  16. pmc Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Blood 119:4129-32. 2012
    ..Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma...
  17. ncbi request reprint Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma
    Ivan Aksentijevich
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 12:965-72. 2006
    ..Auto-BMT and allo-BMT produced similar survival for patients with relapsed DLCL. For patients with sensitive disease, allo-BMT seemed to provide longer survival with less relapse; however, this was achieved at the cost of greater TRM...
  18. pmc Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma
    Javier Bolaños-Meade
    George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 13:1185-91. 2007
    ..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts...
  19. ncbi request reprint Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
    Carol Ann Huff
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 12:414-21. 2006
    ..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD...
  20. pmc Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
    William Matsui
    The Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 68:190-7. 2008
    ..Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury...
  21. ncbi request reprint High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA
    Biol Blood Marrow Transplant 11:93-100. 2005
    ..These data suggest that patients with lymphomatous involvement of the CNS who achieve CNS remission should be offered BMT if it is otherwise indicated...
  22. pmc Use of antineoplastic agents in patients with cancer who have HIV/AIDS
    Michelle A Rudek
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Lancet Oncol 12:905-12. 2011
    ..We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy...
  23. pmc A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening
    Meir Shamay
    Viral Oncology Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Virol 86:5179-91. 2012
    ..However, LANA expression in telomerase immortalized endothelial cells resulted in telomere shortening. In KSHV-infected cells, telomere shortening may be one more mechanism by which LANA contributes to the development of malignancy...
  24. pmc Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma
    Courtney M Shirley
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Blood 117:6297-303. 2011
    ..The effects of thapsigargin on EBV lytic gene expression are also inhibited by C/EBPβ knock-down. Therefore, C/EBPβ mediates the activation of EBV lytic gene expression associated with bortezomib and another UPR inducer...
  25. pmc Circulating clonotypic B cells in classic Hodgkin lymphoma
    Richard J Jones
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Blood 113:5920-6. 2009
    ..Although the clinical significance of circulating clonotypic B cells in HL remains unclear, these data suggest they may be the initiating cells for HL...
  26. doi request reprint Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?
    Richard F Ambinder
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 15:2205-6. 2009
    ..B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion...
  27. pmc Blood and marrow transplant for lymphoma patients with HIV/AIDS
    Nina D Wagner-Johnston
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Curr Opin Oncol 20:201-5. 2008
    ..This review will discuss the role of bone marrow or peripheral stem-cell transplantation as a modality for patients with HIV and lymphoma...
  28. doi request reprint Hematopoietic stem cell transplantation in HIV-1-infected individuals: clinical challenges and the potential for viral eradication
    Christine M Durand
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21087, USA
    Curr Opin Oncol 25:180-6. 2013
    ..We will discuss the challenges of using blood and marrow transplant strategies in this population, as well as the potential impact that hematopoietic stem cell transplantation has on HIV-1 reservoirs and persistence...
  29. ncbi request reprint Immunotherapies for Hodgkin's lymphoma
    Yvette L Kasamon
    Division of Hematologic Malignancies, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Crit Rev Oncol Hematol 66:135-44. 2008
    ..The clinical experience with adoptive immunotherapy of Epstein-Barr virus positive tumors, and with monoclonal antibodies directed against CD30, CD20, and other antigens, is herein reviewed...
  30. pmc Clonal immunoglobulin DNA in the plasma of patients with AIDS lymphoma
    Nina D Wagner-Johnston
    Department of Oncology, Washington University, St Louis, MO, USA
    Blood 117:4860-2. 2011
    ..Ig DNA rearrangements in plasma may be useful as a lymphoma-specific tumor marker, and failure to clear clonal Ig DNA may identify patients at high risk for failure of standard therapy...
  31. pmc Kaposi sarcoma-associated herpesvirus serum DNA and antibodies not associated with subsequent non-Hodgkin lymphoma risk
    Daniel C Beachler
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 56:188-92. 2011
    ..03), but after adjustment, the difference was not significant. Epstein-Barr virus serum DNA was similarly unassociated with NHL as were KSHV antibodies. KSHV is not a primary cause of NHL in HIV-infected men who have sex with men...
  32. ncbi request reprint Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
    Heather Jacene
    Division of Nuclear Medicine, Department of Radiology, Johns Hopkins University, Baltimore, MD, USA
    Mol Imaging Biol . 2016
    ....
  33. pmc Nelfinavir inhibits maturation and export of herpes simplex virus 1
    Nene N Kalu
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
    J Virol 88:5455-61. 2014
    ..Given that NFV is neither a nucleoside mimic nor a known inhibitor of nucleic acid synthesis, this was expected and suggests its potential as a coinhibitor or alternate antiviral therapeutic agent in cases of resistance...
  34. pmc EBV-related lymphomas: new approaches to treatment
    Jennifer A Kanakry
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Cancer Research Building 1, Room 389, Baltimore, MD 21287, USA
    Curr Treat Options Oncol 14:224-36. 2013
    ..EBV vaccine trials in patients with residual or low-bulk EBV-related malignancies or for the prevention of EBV-PTLD in EBV-seronegative patients awaiting solid organ transplantation are ongoing...
  35. pmc CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA
    Meir Shamay
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    J Infect Dis 205:1095-9. 2012
    ..The difference in the origins of cfDNA in these settings may in part reflect very different proliferative indices in KS and PEL tumor tissue...
  36. pmc Cancer biomarkers in HIV patients
    Richard F Ambinder
    Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    Curr Opin HIV AIDS 5:531-7. 2010
    ..In this review, we update investigations related to cancer biomarkers in HIV-infected populations...
  37. pmc A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors
    Jianqing Lin
    Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Clin Cancer Res 15:6241-9. 2009
    ..The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied...
  38. ncbi request reprint AIDS-related primary central nervous system lymphoma
    Yvette L Kasamon
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Hematol Oncol Clin North Am 19:665-87, vi-vii. 2005
    ..The authors focus on commonly encountered diagnostic and therapeutic dilemmas and explore some promises and pitfalls of Epstein-Barr virus-directed therapies...
  39. ncbi request reprint Epstein-Barr virus DNA in body fluids
    Mary Jo Lechowicz
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 14:533-7. 2002
    ..The utility of Epstein-Barr virus DNA detection and quantification in the serum or plasma of patients with HIV malignancies has yet to be determined but holds great promise...
  40. pmc Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy
    Stephanie Gaillard
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Clin Virol 51:195-8. 2011
    ..The data suggests that de-novo antibody responses do not play a significant role in the control of viral replication in these patients...
  41. pmc Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma
    Kimberly A Noonan
    Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 453, Baltimore, MD 21231, USA
    Sci Transl Med 7:288ra78. 2015
    ..1 months versus 11.8 months; P = 0.01). This study demonstrates the feasibility and efficacy of MILs as a form of ACT with applicability across many hematologic malignancies and possibly solid tumors infiltrating the bone marrow. ..
  42. pmc Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage
    Genevieve M Crane
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Oncotarget 6:33849-66. 2015
    ..These findings have significant implications for the transplant community, particularly given the introduction of new regimens lacking calcineurin inhibitors. Further investigation into these associations is warranted. ..
  43. ncbi request reprint Viruses as potential targets for therapy in HIV-associated malignancies
    Richard F Ambinder
    Hematologic Malignancies Division, Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, Bunting Blaustein Building, Room 389, Baltimore, MD 21231, USA
    Hematol Oncol Clin North Am 17:697-702, v-vi. 2003
    ....
  44. ncbi request reprint Posttransplant lymphoproliferative disease: pathogenesis, monitoring, and therapy
    Richard F Ambinder
    Departments of Oncology, Pathology, and Pharmacology, Johns Hopkins University School of Medicine, Suite 389, Bunting Blaustein Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Oncol Rep 5:359-63. 2003
    ..New approaches to adoptive cellular immunotherapy, including use of EBV-specific products from unrelated donors, nonspecifically activated autologous products, and genetically engineered T cells, are all being explored...
  45. pmc Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk
    Elena Vendrame
    Authors Affiliations University of California Los Angeles UCLA AIDS Institute, Jonsson Comprehensive Cancer Center at UCLA, Departments of Obstetrics and Gynecology, Psychiatry and Biobehavioral Sciences, and Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Department of Epidemiology, UCLA School of Public Health, Los Angeles, California Departments of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health and Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois and Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania
    Cancer Epidemiol Biomarkers Prev 23:343-9. 2014
    ..HIV infection is associated with a marked increase in risk for non-Hodgkin lymphoma (AIDS-NHL). However, the mechanisms that promote the development of AIDS-NHL are not fully understood...
  46. pmc Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy
    Qian Tao
    Oncology Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Am J Pathol 160:1839-45. 2002
    ..8 stimulators or vaccine strategies using B95.8-derived sequence will generally target Epstein-Barr virus strains present in posttransplant lymphoproliferative disease tumors...
  47. pmc Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray
    Dasheng Zheng
    Viral Oncology Program, Sidney Kimmel Cancer Center, Baltimore, Maryland, USA
    J Infect Dis 204:1683-91. 2011
    ..Both viruses are associated with malignancies that have an increased frequency in individuals who are coinfected with human immunodeficiency virus type 1 (HIV-1)...
  48. ncbi request reprint Plasma cell dyscrasia, Hodgkin lymphoma, HIV, and Kaposi sarcoma-associated herpesvirus
    Hetty Carraway
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 14:543-5. 2002
    ..As with Hodgkin lymphoma in HIV patients, the presentation is often unusual and aggressive, and these tumors are commonly associated with Epstein-Barr virus. Little evidence suggests a link with Kaposi sarcoma-associated herpesvirus...
  49. pmc Small capsid protein pORF65 is essential for assembly of Kaposi's sarcoma-associated herpesvirus capsids
    Edward M Perkins
    Viral Oncology Program, Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21117, USA
    J Virol 82:7201-11. 2008
    ..Thus, a novel outcome of this study is the finding that the small capsid protein of KSHV, like the major capsid and triplex proteins, is essential for capsid shell assembly...
  50. ncbi request reprint Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Biol Blood Marrow Transplant 11:39-46. 2005
    ..Whether allogeneic BMT ultimately confers an advantage because of a graft-versus-lymphoma effect remains to be determined...
  51. ncbi request reprint Virus-associated tumor imaging by induction of viral gene expression
    De Xue Fu
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Clin Cancer Res 13:1453-8. 2007
    ..The goal of this study is to image EBV-associated tumors by induction of viral TK expression with radiolabeled 2'-fluoro-2'-deoxy-beta-D-5-iodouracil-arabinofuranoside (FIAU)...
  52. ncbi request reprint Hodgkin disease/lymphoma
    Richard T Hoppe
    Stanford Comprehensive Cancer Center, USA
    J Natl Compr Canc Netw 6:594-622. 2008
  53. ncbi request reprint Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma
    Margaret L Gulley
    Department of Pathology, University of Texas Health Science Center at San Antonio, USA
    Am J Clin Pathol 117:259-67. 2002
    ..EBER and LMP1 assays in combination are more effective than either assay alone for identifying EBV-related Hodgkin lymphoma...
  54. pmc Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations
    Sally L Glaser
    Northern California Cancer Center, Fremont, CA 94538, USA
    Int J Cancer 123:1499-507. 2008
    ....
  55. ncbi request reprint Body size, physical activity, and risk of Hodgkin's lymphoma in women
    Theresa H M Keegan
    Northern California Cancer Center, Suite 300, 2201 Walnut Avenue, Fremont, CA 94538 2334, USA
    Cancer Epidemiol Biomarkers Prev 15:1095-101. 2006
    ..These findings show that in women, body size and strenuous physical activity, both modifiable characteristics, are associated with HL risk in adult life possibly through immunologic, infectious, or genetic mechanisms...
  56. ncbi request reprint Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations
    Marta Epeldegui
    Department of Microbiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1740, USA
    Mol Immunol 44:934-42. 2007
    ..These findings indicate that EBV induced AID and pol-eta expression, and that this was associated with oncogene mutation, providing a novel means by which EBV infection of B cells may contribute to lymphomagenesis...
  57. ncbi request reprint Mononucleosis in the laboratory
    Richard F Ambinder
    J Infect Dis 192:1503-4. 2005
  58. ncbi request reprint Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors
    Anthony T C Chan
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin NT, Hong Kong SAR, China
    J Clin Oncol 22:1373-81. 2004
    ..To determine whether therapy with a DNA methyltransferase inhibitor is effective in achieving demethylation and gene re-expression in tumor DNA in patients...
  59. ncbi request reprint Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study
    Theresa H M Keegan
    Northern California Cancer Center, 2201 Walnut Ave, Ste 300, Fremont, CA 94538 2334, USA
    J Clin Oncol 23:7604-13. 2005
    ..This study assessed survival after HL in a population-based cohort large enough to examine the joint effects of EBV with other factors including age, sex, and histologic subtype...
  60. ncbi request reprint Exposure to childhood infections and risk of Epstein-Barr virus--defined Hodgkin's lymphoma in women
    Sally L Glaser
    Northern California Cancer Center, Fremont, CA 94538, USA
    Int J Cancer 115:599-605. 2005
    ..Null findings for EBV-negative HL indicate that etiologic models should be reconsidered for this common form...
  61. ncbi request reprint Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease
    Pauline Meij
    Department of Pathology, VU Medical Center, Amsterdam, The Netherlands
    J Med Virol 68:370-7. 2002
    ..Interestingly, all patients with the strongest antibody responses to LMP1 had EBV-negative tumors, suggesting immunological selection in vivo...
  62. ncbi request reprint Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas
    Jianming Ying
    Cancer Epigenetics Laboratory, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, Chinese University of Hong Kong, Hong Kong, China
    Epigenetics 2:15-21. 2007
    ..Our results indicate that DLC1 methylation is a frequent event in multiple lymphomagenesis and could serve as a tumor-specific biomarker for future lymphoma diagnosis...
  63. ncbi request reprint Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures
    Sally L Glaser
    Northern California Cancer Center, 32960 Alvarado Niles Road, Suite 600, Union City, CA 94587, USA
    Leuk Lymphoma 45:489-97. 2004
    ..The variability in assay interpretation justifies caution in comparing EBV association results across HL studies and underscores the need for interpretation guidelines...
  64. ncbi request reprint Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998
    Sally L Glaser
    Northern California Cancer Center, Union City, California 94587, USA
    Cancer 98:300-9. 2003
    ....
  65. ncbi request reprint Smoking and Hodgkin lymphoma risk in women United States
    Sally L Glaser
    Northern California Cancer Center, 32960 Alvarado Niles Road, Suite 600, Union City, CA 94587, USA
    Cancer Causes Control 15:387-97. 2004
    ..We investigated the association of HL with lifetime cigarette smoking and household environmental tobacco smoke (ETS) exposure in women...